Steinhart Richard I — SEC insider filings

SEC reporting owner CIK 1293789. 39 insider filings on record with FilingPulse; latest filed 2026-09-04.

Transaction summary — filings shown

Covers all 39 filings on record, filed 2020-08-14 to 2026-09-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
BioXcel Therapeutics, Inc. (BTAI)Chief Financial Officer27—10 legs · 27,228 sh · $372,17669
Actinium Pharmaceuticals, Inc. (ATNM)Director6——14
ATOSSA THERAPEUTICS, INC. (ATOS)Director6——6

Insider filings — Steinhart Richard I

FiledFormIssuerReported transactionsSource
2026-09-044Actinium Pharmaceuticals, Inc. (ATNM)Grant/award (A): 62,800 @ $0 · Grant/award (A): 94,200 (derivative) @ $0EDGAR
2026-06-174BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 35 · Option exercise (M): 35 (derivative) @ $0EDGAR
2026-05-224BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 17,500 · Sale (S): 6,845 @ $1.08 · Option exercise (M): 17,500 (derivative) @ $0EDGAR
2026-05-144ATOSSA THERAPEUTICS, INC. (ATOS)Grant/award (A): 10,000 @ $0EDGAR
2026-05-074BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 9,000 · Option exercise (M): 9,000 (derivative) @ $0EDGAR
2026-03-164BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2026-01-054BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 70,000 (derivative) @ $0EDGAR
2025-12-154BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2025-09-164BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2025-08-054BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 9,000 (derivative) @ $0EDGAR
2025-07-224BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 4,375 · Option exercise (M): 625 · Option exercise (M): 625 (derivative) @ $0EDGAR
2025-06-164BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 33 · Option exercise (M): 35 · Option exercise (M): 33 (derivative) @ $0 · Option exercise (M): 35 (derivative) @ $0EDGAR
2025-05-164ATOSSA THERAPEUTICS, INC. (ATOS)Grant/award (A): 125,000 (derivative) @ $0EDGAR
2025-04-024Actinium Pharmaceuticals, Inc. (ATNM)Disposition to issuer (D): 2,500 (derivative) @ $0 · Disposition to issuer (D): 2,500 (derivative) @ $0 · Disposition to issuer (D): 2,500 (derivative) @ $0 · Disposition to issuer (D): 8,333 (derivative) @ $0 · Disposition to issuer (D): 8,333 (derivative) @ $0 · Disposition to issuer (D): 18,351 (derivative) @ $0 · +2 moreEDGAR
2025-04-014BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 625 (derivative) @ $0 · Grant/award (A): 1,875 (derivative) @ $0EDGAR
2025-03-174BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 31 · Option exercise (M): 34 · Option exercise (M): 31 (derivative) @ $0 · Option exercise (M): 34 (derivative) @ $0EDGAR
2025-01-104BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 270,000 (derivative) @ $0EDGAR
2024-12-174BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 521 · Option exercise (M): 562 · Sale (S): 205 @ $0.36 · Sale (S): 372 @ $0.36 · Option exercise (M): 521 (derivative) @ $0 · Option exercise (M): 562 (derivative) @ $0EDGAR
2024-10-034BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 21,250 · Sale (S): 7,175 @ $0.55EDGAR
2024-09-174BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 521 · Option exercise (M): 563 · Sale (S): 356 @ $0.69 · Option exercise (M): 521 (derivative) @ $0 · Option exercise (M): 563 (derivative) @ $0EDGAR
2024-07-014ATOSSA THERAPEUTICS, INC. (ATOS)Grant/award (A): 125,000 (derivative) @ $0EDGAR
2024-06-184BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 521 · Option exercise (M): 562 · Sale (S): 372 @ $1.26 · Option exercise (M): 521 (derivative) @ $0 · Option exercise (M): 562 (derivative) @ $0EDGAR
2024-04-084BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 521 · Option exercise (M): 2,250 · Sale (S): 1,069 @ $2.63 · Option exercise (M): 521 (derivative) @ $0 · Option exercise (M): 2,250 (derivative) @ $0EDGAR
2023-12-294Actinium Pharmaceuticals, Inc. (ATNM)Grant/award (A): 70,311 (derivative) @ $0EDGAR
2023-12-184BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 521 · Option exercise (M): 521 (derivative) @ $0EDGAR
2023-09-184BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 521 · Option exercise (M): 521 (derivative) @ $0EDGAR
2023-06-164BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 521 · Option exercise (M): 521 (derivative) @ $0EDGAR
2023-05-164BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 5,000 · Sale (S): 5,000 @ $27.17 · Option exercise (M): 5,000 (derivative) @ $0EDGAR
2023-05-054ATOSSA THERAPEUTICS, INC. (ATOS)Grant/award (A): 125,000 (derivative) @ $0EDGAR
2023-03-164BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 2,084 · Sale (S): 2,084 @ $19.50 · Option exercise (M): 2,084 (derivative) @ $0 · Grant/award (A): 9,000 (derivative) @ $0 · Grant/award (A): 32,000 (derivative) @ $0EDGAR
2022-07-014Actinium Pharmaceuticals, Inc. (ATNM)Grant/award (A): 72,156 (derivative) @ $0EDGAR
2022-05-174BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 5,000 (derivative) @ $0EDGAR
2022-05-164ATOSSA THERAPEUTICS, INC. (ATOS)Grant/award (A): 50,000 (derivative) @ $0EDGAR
2022-03-164BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 8,337 (derivative) @ $0 · Grant/award (A): 33,350 (derivative) @ $0EDGAR
2021-09-034Actinium Pharmaceuticals, Inc. (ATNM)Grant/award (A): 18,351 (derivative) @ $0EDGAR
2021-05-184ATOSSA THERAPEUTICS, INC. (ATOS)Grant/award (A): 50,000 (derivative) @ $0EDGAR
2021-03-294BioXcel Therapeutics, Inc. (BTAI)Grant/award (A): 20,000 (derivative) @ $0EDGAR
2021-02-034BioXcel Therapeutics, Inc. (BTAI)Option exercise (M): 3,750 @ $5.55 · Sale (S): 3,750 @ $48.15 · Option exercise (M): 3,750 (derivative) @ $0EDGAR
2020-08-144Actinium Pharmaceuticals, Inc. (ATNM)Grant/award (A): 8,333 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1293789 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs